Insider Selling: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider Sells 10,223 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 10,223 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $14.73, for a total transaction of $150,584.79. Following the sale, the insider now directly owns 612,646 shares of the company’s stock, valued at approximately $9,024,275.58. The trade was a 1.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.77, for a total transaction of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total value of $253,296.84.

Eton Pharmaceuticals Price Performance

ETON opened at $13.61 on Wednesday. The stock has a market capitalization of $365.02 million, a P/E ratio of -75.61 and a beta of 1.28. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.97 and a quick ratio of 1.43. The company’s 50 day simple moving average is $16.61 and its 200-day simple moving average is $15.04. Eton Pharmaceuticals, Inc. has a one year low of $3.18 and a one year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. Sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at about $662,000. Millennium Management LLC bought a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $1,850,000. Balyasny Asset Management L.P. bought a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $158,000. Two Sigma Investments LP bought a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $1,498,000. Finally, Jane Street Group LLC boosted its stake in Eton Pharmaceuticals by 328.6% in the fourth quarter. Jane Street Group LLC now owns 64,323 shares of the company’s stock valued at $857,000 after acquiring an additional 49,317 shares during the last quarter. Institutional investors own 27.86% of the company’s stock.

Wall Street Analysts Forecast Growth

ETON has been the topic of a number of research analyst reports. Craig Hallum increased their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. HC Wainwright restated a “buy” rating and set a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Finally, B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.